Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide vs continued GLP-1 receptor agonist on oxidative stress and glucose variability in type 2 diabetes
jRCT1031230368Active, not recruiting
- Sponsor
- SHOWA Medical University Hospital
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Trial of tirzepatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by SHOWA Medical University Hospital. Primary endpoint: Change in d-ROMs (oxidative stress marker) from baseline to 24 weeks. Started Mar 2024; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1031230368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230368.